$0.28
+0.00 (+1.57%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where IGC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 4 tracked-famous managers (CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 1.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Clinical Trial on Agitation in Alzheimer's DementiaNCT05543681AgitationRandomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: IGC-AD1-Active, IGC-AD1-Placebo | Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression | 164 | Aug 2026 | ≤ 12 d | 2026-05-20 |
| Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's DiseaseNCT04749563Incidence of treatment-emergent adverse events in IGC-AD1 as compared to placebo [Safety and Tolerability]Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: IGC AD1, Placebo | Dementia of Alzheimer Type | 12 | 2021-06-20actual | — | 2022-09-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19